Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Could Start Testing a Coronavirus Cocktail Therapy by Early Summer

By Keith Speights - Updated Mar 17, 2020 at 10:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker will pick the two most promising antibodies out of hundreds that it has isolated to target the novel coronavirus.

Regeneron Pharmaceuticals (REGN 0.72%) announced on Tuesday that its scientists have identified hundreds of viral-neutralizing antibodies that could potentially be used to protect against and treat the novel coronavirus that causes COVID-19. The company stated that it plans to pick the top two antibodies to include in a cocktail therapy for COVID-19, and hopes to begin clinical testing of a treatment in humans by early summer. By using more than one variety of antibody, the treatment will be able to target different parts of the coronavirus, which could make it effective against more viral variants. 

Mixing the cocktail

Antibodies target disease-causing pathogens in the blood, including viruses. Regeneron has isolated antibodies from mice that were genetically modified to have the same immune system as humans have. It also isolated antibodies from individuals who have recovered from COVID-19 to find those that could be most effective at targeting SARS-CoV-2, the coronavirus that causes this illness. 

Man wearing a protective mask and glasses holding a vial labeled with "coronavirus"

Image source: Getty Images.

After the top two most promising antibodies are selected, Regeneron will replicate small quantities of them to evaluate in a phase 1 study. The hope is that the resulting treatment will be effective both as one that can be given before exposure to the coronavirus and for individuals who have already been infected. The drugmaker is ramping up to produce hundreds of thousands of doses per month by the end of the summer.

Other efforts

In addition to its experimental cocktail therapy, Regeneron and its partner, Sanofi, have begun a phase 2/3 clinical study evaluating rheumatoid arthritis drug Kevzara as a treatment for patients with severe cases of COVID-19. It's believed that Kevzara could help alleviate the inflammation in the lungs that features in the most dangerous cases of the disease.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$595.40 (0.72%) $4.27
Sanofi Stock Quote
Sanofi
SNY
$51.01 (1.96%) $0.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.